linjc16/ctgov huggingface dataset:
Correlation Between the Volume Flow of the CFA After Angioplasty of Critical Ischemic Limb and Wound Healing

Study Overview
=================
Brief Summary
-----------------
in our study we are examining the volume flow of the common femoral artery before and after angigraphy of a critical ischemic limb, as a predictor for wound healing after the treatment

Detailed Description
-----------------
All patients with threatened limbs, that was decided upon to have angioplasty will be asked to sign consent form to participate in this study. Before having the angioplasty, all participants will be examined with ultrasound duplex to determent their common femoral artery volume flow. Day after the angioplasty, they will be reexamined (this is the usual practice) to detriment the new volume flow in the CFA. The participents examinations in the outpatient clinics will be documented and time for healing will be recorded.

Official Title
-----------------
Correlation Between the Volume Flow of the CFA After Angioplasty of Critical Ischemic Limb and Wound Healing

Conditions
-----------------
Wound Heal, Duplex Volume Flow

Intervention / Treatment
-----------------
* Diagnostic Test: duplex ultrasound for the common femoral artery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with threatened limbs, that was decided upon to have angioplasty . Exclusion Criteria: those who are not willing to sign a consent form to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: duplex ultrasound for the common femoral artery|duplex ultrasound for the common femoral artery before and after the angiography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| wound healing | physical examination | 12 months |
Effect of Cavotricuspid Isthmus Ablation in Patients Without History of Typical Flutter During Ablation

Study Overview
=================
Brief Summary
-----------------
It has been demonstrated that successful cavotricuspid isthmus ablation may be effective in preventing paroxysmal atrial fibrillation. However, the effectiveness of only isthmus ablation on atrial fibrillation itself is unclear.

Detailed Description
-----------------
Researchers hypothesized that an organized activation pattern around the tricuspid annulus during atrial fibrillation indicated a mother reentrant circuit that could be terminated by a cavocaval isthmus ablation, thus preventing atrial fibrillation. The objectives of the present study were to evaluate the effectiveness of isthmus ablation in preventing atrial fibrillation and to identify predictors of its success.

Official Title
-----------------
Effect of Cavotricuspid Isthmus Ablation in Patients Without History of Typical Flutter During Ablation for Paroxysmal Atrial Fibrillation

Conditions
-----------------
Paroxysmal Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: cavotricuspid isthmus ablation
* Procedure: control group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled ablation for paroxysmal atrial fibrillation Exclusion Criteria: Typical atrial flutter History of artificial tricuspid valve surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: cavotricuspid isthmus ablation<br>Isthmus ablation was performed in paroxysmal atrial fibrillation patients. | Procedure: cavotricuspid isthmus ablation<br>* Isthmus ablation was performed in paroxysmal atrial fibrillation patients.<br>|
| Placebo Comparator: control group<br>Control group was performed no additional cavotricuspid isthmus ablation. | Procedure: control group<br>* Control group was performed no additional cavotricuspid isthmus ablation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Freedom of AF and Af | 1 month, 3 months and 12months after ablation follow up visit and Check the recurrence of atrial fibrillation through EKG,Holter, event recording | 1 year after catheter ablation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Catheter ablation, Fibrillation
CARE Canadian ALS Riluzole Evaluation

Study Overview
=================
Brief Summary
-----------------
Evaluate the efficacy of riluzole 50-mg bid defined by comparing the percentage of riluzole-treated subjects who experienced death, permanently assisted ventilation (PAV) or tracheostomy, to a group of recent historical controls for the treatment of amyotrophic lateral sclerosis (ALS).

Official Title
-----------------
Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls

Conditions
-----------------
Amyotrophic Lateral Sclerosis

Intervention / Treatment
-----------------
* Drug: Riluzole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of ALS confirmed by the following definition: (a)Probable or Definite Amyotrophic Lateral Sclerosis (ALS) according to the El Escorial criteria(b)Peripheral onset form (limb involvement) or a Bulbar form of ALS with a duration of five years, based on inquiry for the earliest symptoms of the disease A subject who simultaneously presents with bulbar and peripheral signs at onset of ALS disease should be stratified to the bulbar onset group. The neurologic progression of such subjects matches that of the bulbar onset ALS subjects. Pulmonary Function: forced vital capacity (FVC) must be 3 60% at study entry. Females of childbearing potential must be documented to be using acceptable birth control methods such as an IUD or oral contraceptives. Exclusion Criteria: Previous treatment with riluzole Tracheostomy, or expected to undergo a tracheostomy within two months after study inclusion Signs of clinical dementia and/or major psychiatric disorders Serious concomitant disease or handicap likely to interfere with the subject's assessments or impact on the subject's survival A multiple conduction block has been shown on nerve conduction studies by electromyogram The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Riluzole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary efficacy endpoint was the time to the occurrence of an ALS-related event (PAV, tracheostomy or ALS-related death) |  |  |
Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Insulin-like Growth Factor II is elevated sufficiently to detect Cervical Intraepithelial Neoplasia II (CIN II), Cervical Intraepithelial Neoplasia III (CIN III), and cervical cancer.

Official Title
-----------------
Phase 1 of Serum IGF II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer

Conditions
-----------------
Cervical Cancer, Cervical Intraepithelial Neoplasia II, Cervical Intraepithelial Neoplasia III

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 - 75 years Female Normal medical history Medical history of a single type of cancer confirmed by biopsy or equivalent criteria Squamous cell carcinoma of organs other than cervix Adenocarcinoma Medical history of inflammatory disease May be pregnant Pap smear positive for Cervical Intraepithelial Neoplasia II or III Squamous cell cervical cancer confirmed by biopsy Informed consent Willingness to submit a blood sample by venipuncture Willingness to submit a second blood sample if necessary Exclusion Criteria: Age < 18 or > 75 years Medical history of cancer other than cervical cancer, Non-islet-cell tumor hypoglycemia, Growth hormone deficiency, Acromegaly, Hepatoma, inflammatory disease in addition to confirmed CIN and cervical cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IGF-II levels
Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Compare the efficacy of hydroxyurea with or without clotrimazole in terms of limiting the severity of anemia and the rate of hemolysis in patients with sickle cell anemia.

Detailed Description
-----------------
PROTOCOL OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms. Arm I: Patients receive oral hydroxyurea and oral clotrimazole daily for 12 months. Arm II: Patients receive oral hydroxyurea daily for 12 months. Patients are followed at 6 weeks. Completion date provided represents the completion date of the grant per OOPD records

Conditions
-----------------
Sickle Cell Anemia

Intervention / Treatment
-----------------
* Drug: clotrimazole
* Drug: hydroxyurea


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnosis of sickle cell anemia confirmed by hemoglobin electrophoresis Received hydroxyurea for at least 6 months On a stable dose for at least 3 months Tolerating dose of at least 5 mg/kg/day --Prior/Concurrent Therapy-- Chemotherapy: No other concurrent antisickling agent Other: No concurrent drug that may interact with or influence the metabolism of hydroxyurea or clotrimazole --Patient Characteristics-- Hematopoietic: WBC at least 4000/mm3 Platelet count at least 150,000/mm3 Hemoglobin less than 11 g/dL Hepatic: AST/ALT no greater than 100 units/L Renal: Creatinine no greater than 1.5 mg/dL Other: Not pregnant or nursing Fertile patients must use effective contraception No prior adverse reaction to hydroxyurea or clotrimazole No recent or progressive neurologic dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: clotrimazole|nan|
|Drug: hydroxyurea|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genetic diseases and dysmorphic syndromes, hematologic disorders, rare disease, sickle cell anemia
Pain Characteristics After Total Laparoscopic Hysterectomy

Study Overview
=================
Brief Summary
-----------------
Laparoscopic operative procedures have revolutionized gynecological surgery. These have several advantages: a smaller and more cosmetic incision, reduced blood loss and shorter postoperative stay, which cuts down on hospital costs. However, postoperative pain continues to be one complication, which results in an unpleasant experience for the patient and at times causes a delayed discharge. There are few studies about pain characteristics as one of laparoscopic hysterectomy complications. The purpose of this study is to investigate the prevalence and characteristics of shoulder pain, headache, abdominal pain, and back pain in patients undergoing total laparoscopic hysterectomy.

Conditions
-----------------
Myoma of Uterus

Intervention / Treatment
-----------------
* Device: classic LMA insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I or II age >=20, <= 80 years female patients undergoing elective total laparoscopic hysterectomy Exclusion Criteria: age < 19 years or > 80 years abnormal mental status drug abuse chronic alcoholism immunosuppressants or steroid user

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: laparoscopic hysterectomy group<br>female patients undergoing total laparoscopic hysterectomy. | Device: classic LMA insertion<br>* Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall pain | evaluated with visual analogue score (VAS) | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, total laparoscopic hysterectomy
Candidemia in a Pediatric Center and Importance of Central Venous Catheter Removal

Study Overview
=================
Brief Summary
-----------------
Candidemia has emerged as an important cause of hospital-associated blood-stream infection in children. The purpose of this study was to identify differences in distribution of candida species, risk factors, treatment, and clinical outcome of candidemia in children. This study in children ≤18 years with blood culture proven candidemia identified between 2004 and 2012. Analyses included the determination of causative candida species, resistance to antifungals and clinical outcome, as well as the identification of potential risk factors associated with candidemia.

Conditions
-----------------
Candidemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of growth of any candida species in at least one blood culture Exclusion Criteria: Febrile neutropenic patients who were using empirical antifungal agents

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Candidemia<br>Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors of candidemia | The presence or absence of potential risk factors for candidemia such as an indwelling central venous catheter (CVC), use of antibiotics (administered for >72 hours), use of antifungals (administered for >24 hours), immunosuppressants, total parenteral nutrition (TPN), admission to the intensive care unit (ICU), mechanical ventilation, neutropenia, hypoalbuminemia and hypophosphatemia. | up to 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prognosis according to candida species | Death which ensues within 30 days of the onset of candidemia with no apparent alternative cause is recognized as a candidemia-attributable mortality. Patients who died and survived were compared according to candida species (C.albicans, C. parapsilosis, C. tropicalis, C. sake, C.glabrata). | up to 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
candidemia, children, mortality, risk factors
Microbial Community Composition and Metabolism in Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
Scientist have begun to realize that many types of bacteria often live together as a complex community, and the investigators wish to apply that idea to the bacteria in the respiratory system of people with Cystic Fibrosis (CF). It is possible that the survival of the many millions of bacteria in the CF lung depends on the production of special chemicals that might be made only by very few types of bacteria. If that is true, medicines that interfere with those chemicals could treat the lung infections that cause trouble for nearly all people with CF. The investigators wish to study the production of several potentially critical chemicals by the respiratory bacteria and to examine the effect of those chemicals on the makeup of the entire community of bacteria. To detect all the bacteria in that community, the investigators will use new methods that use bacterial genetic information and can detect hundreds of different types of bacteria in respiratory samples of individual CF patients.

Official Title
-----------------
Respiratory Microbial Community Composition and Metabolism in Cystic Fibrosis

Conditions
-----------------
Cystic Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed diagnosis of Cystic Fibrosis 2 to 55 years of age Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cystic Fibrosis patient during outpatient clinic visit<br> | |
| Cystic Fibrosis patients during hospitalization<br> | |
| CF patients about to have sinus surgery and bronchoscopy<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Blood Pressure Analysis on Critically Ill Patients

Study Overview
=================
Brief Summary
-----------------
The study is to explore the relationship between coefficient of variation of harmonic magnitude (HCV) and different organ failures among those critically ill patients. In the future, we can act as a warning system on patients with multiple organ failures or terminal illness, also as an indicator of treatment effect.

Official Title
-----------------
The Blood Pressure Analysis on Critically Ill Patients

Conditions
-----------------
Multiple Organ Failure, Intensive Care Unit Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: ICU patient


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU patients in the 20-to-99 age range Subjects agree to sign the Informed Consent Form and are willing to cooperate with Arterial pulse measurement Exclusion Criteria: Subject has severe arrhythmia

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ICU patient<br>Pulse pressure of the radical artery was obtained by arterial line. The output of the transducer was connected to an IBM PC for analysis via an A/D converter with sampling rate = 250 datapoints/sec. The pulse spectrum was analyzed with the Fourier transformation using T (period) = 1 pulse time. | Diagnostic Test: ICU patient<br>* Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coefficient of variation of harmonic magnitude | We measure the blood pressure of participants with multiple organ failures (MOF) by pressure transducer during the 6 months study in the ICU of Taoyuan General Hospital. The radial artery pressure pulse of both hands are recorded with a pressure transducer fixed on the skin with tape and an adjustable belt with a small button to achieve suitable pressure. | 15 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood pressure, Arterial pulse, Coefficient of variation of harmonic magnitude